Self‐boosting programmable release of multiple therapeutic agents by activatable heterodimeric prodrug‐enzyme assembly for antitumor therapy
Loading...
Author (Corporation)
Publication date
01.2025
Type of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
Advanced Science
Special issue
DOI of the original publication
Link
Series
Series number
Volume
12
Issue / Number
2
Pages / Duration
2409960
Patent number
Publisher / Publishing institution
Wiley
Place of publication / Event location
Edition
Version
Programming language
Assignee
Practice partner / Client
Abstract
Endogenous stimuli-responsive prodrugs, due to their disease lesion specificity and reduced systemic toxicity, have been widely explored for antitumor therapy. However, reactive oxygen species (ROS) as classical endogenous stimuli in the tumor microenvironment (TME) are not enough to achieve the expected drug release. Herein, a ROS-activatable heterodimeric prodrug-loaded enzyme assembly is developed for self-boosting programmable release of multiple therapeutic agents. The heterodimeric prodrug NBS-TK-PTX (namely NTP) is composed of 5-(ethylamino)-9-diethylaminobenzo[a]phenothiazinium chloride analog (NBS), paclitaxel (PTX) and ROS-responsive thioketal (TK) linker, which shows a strong binding affinity with glucose oxidase (GOx), thus obtaining NTP@GOx assembly. Notably, the enzymatic activity of GOx in NTP@GOx is inhibited by NTP. The programmable release is achieved by following steps: i) NTP@GOx is partially dissociated in acidic TME, thus releasing a small segment of NTP and GOx. Thereupon, the enzymatic activity of GOx is recovered; ii) GOx-triggered pH reduction further facilitates the dissociation of NTP@GOx, thus accelerating a large amount of NTP and GOx release; iii) The TK linker of prodrug NTP is cleaved by hydrogen peroxide generated by GOx catalysis, thus expediting the release of NBS for Type-I photodynamic therapy and PTX for chemotherapy, respectively. The NTP@GOx shows great potential for multimodal synergistic cancer therapy.
Keywords
antitumor therapy, glucose oxidase, heterodimeric prodrug, reactive oxygen species, self-boosted programmable release
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
2198-3844
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Future Health
Publication status
Published
Review
Peer review of the complete publication
Open access category
Gold
Citation
Jiang, S., Gurram, B., Zhu, J., Lei, S., Zhang, Y., He, T., Tagit, O., Fang, H., Huang, P., & Lin, J. (2025). Self‐boosting programmable release of multiple therapeutic agents by activatable heterodimeric prodrug‐enzyme assembly for antitumor therapy. Advanced Science, 12(2), 2409960. https://doi.org/10.1002/advs.202409960